U.S. Uterine Fibroid Market: Development History, Current Analysis and Estimated Forecast to 2027
U.S. Uterine Fibroid Market Information
By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and
others), By Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed
Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid
Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis,
Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2027
U.S. Uterine Fibroid Market Highlights
Market Research Future (MRFR)
speculates that the U.S.
uterine fibroid market is likely to garner USD 39,993.2 million,
grabbing a CAGR of 3.24% during the forecast period (2016-2022). The surging
prevalence of uterine fibroid in the African-American race is considered a
propelling factor to the growth of the market. Uterine fibroids can be referred
to as the abnormal growth which generally develops inside or on the wall of the
uterus of a woman. Also termed as myomas or leiomyoma, uterine fibroids are
non-cancerous growth which causes symptoms like pain in the pelvis and lower
back, heavy bleeding during or between the menstrual cycle, and increased
menstrual cramps along with the enlargement of the abdomen.
Market Potential and Pitfalls
Uterine fibroids are spreading
over the entire U.S. at a rapid pace mainly due to the increased prevalence of
uterine fibroids in the African-American race. The high blood pressure, the
heredity of uterine fibroids, and low levels of vitamin D are considered some
of the top factors causing uterine fibroids. The U.S. uterine fibroid market is
anticipated to touch high growth figures in the long run mainly due to the
surging prevalence of uterine fibroids and the rising number of hysterectomy
surgeries every year. Several treatment options available such as
pharmacotherapy, self-help techniques, invasive surgical procedures, and
uterine artery embolization are propelling the market growth in the U.S.
The introduction of minimally
invasive surgeries such as myomectomy and hysterectomy for treating the
excruciating pain of uterine fibroids is expected to encourage the market
growth. Such surgeries have reduced the chances of infection, reduced the
hospital stay, and, lowered the recovery time, thereby contributing to the
growth. Moreover, the advancing technology coupled with the increased
activities on research and development is some of the top factors predicted to
accelerate the market growth during the review period.
On the contrary, it has also
been observed that the procedures such as myomectomy and hysterectomy are
covering the uterine Fibroid treatment despite the side effects associated with
it. This has resulted in limited treatment options for uterine fibroids.
Moreover, the high cost-containment measures undertaken by governments along
with the ongoing healthcare reforms are restricting the market growth in the
U.S.
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/2394
U.S. Uterine Fibroid Market:
Segmental Analysis
The U.S. uterine fibroid market
has been segmented on the basis of type, diagnosis, and treatment.
By mode of type, the U.S.
uterine fibroid market has been segmented into intramural fibroids, sub serosal
fibroids, submucosal fibroids, and others.
By mode of diagnosis, the U.S.
uterine fibroid market has been segmented into computed tomography (CT),
medical resonance imaging (MRI) scanners, ultrasounds, and others.
By mode of treatment, the U.S.
uterine fibroid market has been segmented into magnetic resonance-guided
focused ultrasound, uterine fibroid embolization, endometrial ablation,
myolysis, hysterectomy, and myomectomy. Among these, hysterectomy and myomectomy
are minimally invasive surgeries which are likely to gain prominence in the
long run. These surgeries being minimally invasive, reduces the chances of
infection after surgery, shorter hospital stays, and minimal recovery time.
These advantages of hysterectomy and myomectomy are likely to contribute to the
segment’s growth.
Regional Insights
The U.S. uterine fibroid market
is expanding at a steady pace with a CAGR of 3.24% by the end of 2022.Economies
like Texas, California, New York, and Florida are estimated to witness the
highest prevalence of uterine fibroids. North America has been recorded to
witness the largest market share due to the increased awareness among the
population of the region, easy accessibility to advanced technologies, and an
established healthcare sector. The presence of a high number of clinics and
ambulatory surgical centers and hospitals in this region has further contributed
to the market’s growth. A huge number of people are undergoing hormonal
disorders which are further encouraging the market growth. Moreover, the
increased incidences of uterine cancer is another propelling factor.
Industry Updates
April 19, 2019: A new treatment
for uterine fibroids offered by Gynecologist Dr. Jessica Shepherd has ensured
women to reduce the symptoms of the disease and have the option for a baby. The
minimally invasive procedure termed laparoscopic radiofrequency ablation has
been proven to shrink the fibroids by 40% and also reduce the bleeding during
periods.
Competitive Dashboard
The prominent players operating
the U.S. uterine fibroids market comprises Cook Medical Inc. (US), AstraZeneca
(England), GE Healthcare (U.K.), Boston Scientific Corporation (US), Hologic
(U.S.), AbbVie Inc. (U.S.),and others.
Browse Detailed TOC with
COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394
About
Market Research Future:
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email:
sales@marketresearchfuture.com
Comments
Post a Comment